AcoramidisAttruby®
Transthyretin amyloid cardiomyopathy (ATTR-CM)
List acoramidis for treatment of ATTR-CM with NYHA class I-II heart failure at initiation.
The record First appearance in the PSD record.
Cycle Briefing
November 2026 PBAC Meeting
The committee meets on 6 November 2026. 17 items are on the published agenda — 9 drugs already in the record, 8 appearing for the first time.
Every line below is computed from the published agenda and the extracted PSD record — no estimates.
Get the next one by email
The briefing follows every PBAC cycle — agenda before the meeting, outcomes when they land. Free, one email per cycle event.
No password — a magic link registers you. Registration also unlocks grounded answers in search.
AfliberceptEylea®
Branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) with macular oedema
List 8 mg strength for treatment of visual impairment due to macular oedema secondary to BRVO or CRVO.
The record 15 prior decisions on record (2012–2025); most recently recommended in 2025. Full history →
AumolertinibVelarion®
Non-small cell lung cancer (NSCLC)
List aumolertinib for first and second-line treatment of Stage IIIB/IV NSCLC with EGFR mutation.
The record First appearance in the PSD record.
BaxdrostatBaxfendy®
Hypertension
List baxdrostat for treatment of uncontrolled and resistant hypertension despite two or more antihypertensives.
The record First appearance in the PSD record.
CannabidiolEpidyolex®
Seizures associated with tuberous sclerosis complex (TSC)
List cannabidiol as add-on therapy for drug-resistant epilepsy in TSC patients.
The record 5 prior decisions on record (2020–2026); most recently recommended in 2026. Full history →
ClesrovimabEnflonsia®
Prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV)
List clesrovimab for RSV prevention in young infants and children up to 24 months with risk factors.
The record First appearance in the PSD record.
Datopotamab DeruxtecanDatroway®
Breast cancer
List datopotamab deruxtecan for first-line treatment of metastatic triple-negative breast cancer.
The record First appearance in the PSD record.
DrospirenoneSlindelle®
Contraception and endometriosis-associated pelvic pain (EAPP)
List drospirenone for contraception and management of EAPP.
The record 1 prior decision on record (2024); most recently recommended in 2024. Full history →
Efgartigimod AlfaVyvgart®
Chronic inflammatory demyelinating polyneuropathy (CIDP)
Resubmission to list efgartigimod alfa for CIDP in patients with ongoing disability despite Ig or alternative regimens.
The record 3 prior decisions on record (2025–2026); most recently recommended in 2026. Full history →
Enfortumab VedotinPADCEV®
Muscle-invasive bladder cancer (MIBC)
List enfortumab vedotin with pembrolizumab for perioperative treatment of non-metastatic MIBC.
The record 3 prior decisions on record (2022–2024); most recently recommended in 2024. Full history →
EpcoritamabEpkinly®
Relapsed or refractory (R/R) follicular lymphoma (FL)
List epcoritamab with rituximab and lenalidomide for R/R FL after one or more prior lines.
The record 1 prior decision on record (2024); most recently recommended in 2024. Full history →
IvosidenibTibsovo®
Acute myeloid leukaemia (AML)
List ivosidenib for newly diagnosed IDH1-mutation positive AML ineligible for intensive chemotherapy.
The record 2 prior decisions on record (2024); most recently recommended in 2024. Full history →
MetreleptinMyalepta®
Lipodystrophy
List metreleptin for leptin-deficient lipodystrophy with uncontrolled metabolic complications.
The record First appearance in the PSD record.
Mifepristone And MisoprostolMS-2 Step®
Management of miscarriage
List mifepristone and misoprostol for management of missed miscarriage up to 70 days.
The record 3 prior decisions on record (2013–2023); most recently recommended in 2023. Full history →
NerandomilastJascayd®
Idiopathic pulmonary fibrosis (IPF)
List nerandomilast for treatment-naïve IPF or after nintedanib/pirfenidone discontinuation.
The record First appearance in the PSD record.
NerandomilastJascayd®
Progressive pulmonary fibrosis (PPF)
List nerandomilast for treatment-naïve PPF or after nintedanib discontinuation.
The record First appearance in the PSD record.
NusinersenSpinraza®
Spinal muscular atrophy (SMA)
List two new strengths of nusinersen for SMA populations currently eligible.
The record 9 prior decisions on record (2017–2023); most recently recommended in 2023. Full history →
Outcomes for this meeting are usually published 6–8 weeks after — they appear on Latest as they land, and the next briefing follows the cycle.